Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the one-year and two-year risk of each of the
following individual outcomes: Stroke and systemic embolism (SE), major bleeding and death
between new users of anticoagulant for Stroke prevention in atrial fibrillation (SPAF) during
drug exposure: rivaroxaban versus Vitamin K antagonists (VKA), and rivaroxaban versus
dabigatran